Sandbox Reserved 712: Difference between revisions

Revision as of 16:23, 27 December 2012 view source Angelika Wackerl (talk \| contribs) 209 edits →'''Description''' ← Older edit		Revision as of 16:35, 27 December 2012 view source Angelika Wackerl (talk \| contribs) 209 edits No edit summary Newer edit →
Line 15:		Line 15:

	3ggu (also PR<sub>DRV5</sub>) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref name="Molecular"> PMID:19535439 </ref>		3ggu (also PR<sub>DRV5</sub>) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref name="Molecular"> PMID:19535439 </ref>


	== '''Activity''' ==		== '''Activity''' ==

Navigation menu